Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:76-83
Published online before print November 6, 2006, doi: 10.1161/01.HYP.0000250831.52876.cb
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
49/1/76    most recent
01.HYP.0000250831.52876.cbv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chelbi, S. T.
Right arrow Articles by Vaiman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chelbi, S. T.
Right arrow Articles by Vaiman, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Risk Pregnancy
Related Collections
Right arrow Other hypertension
Right arrow Fibrinolysis
Right arrow Coagulation inhibitors
Right arrow Platelets

(Hypertension. 2007;49:76.)
© 2007 American Heart Association, Inc.


Original Articles

Expressional and Epigenetic Alterations of Placental Serine Protease Inhibitors

SERPINA3 Is a Potential Marker of Preeclampsia

Sonia T. Chelbi; Françoise Mondon; Hélène Jammes; Christophe Buffat; Thérèse-Marie Mignot; Jorg Tost; Florence Busato; Ivo Gut; Régis Rebourcet; Paul Laissue; Vassili Tsatsaris; François Goffinet; Virginie Rigourd; Bruno Carbonne; Françoise Ferré; Daniel Vaiman

From the Equipe 21 (S.T.C., F.M., H.J., T.-M.M., R.R., P.L., B.C., V.R., B.C., F.F., D.V.), Génomique et Epigénétique des Pathologies Placentaires, Unité INSERM 567/UMR Centre National de la Recherche Scientifique 8104, Université Paris V IFR Alfred Jost, Faculté de Médecine, Cochin-Port-Royal, Paris, France; PHASE Department (H.J.), Institut National de la Recherche Agronomique, Jouy-en-Josas, France; Faculté de Médecine (C.B.), Université de la Méditerranée et Service de Néonatologie, Hôpital de la Conception AP-HM, Marseille, France; Laboratoire d’épigénétique (J.T., F.B., I.G.), Centre National de Génotypage, Evry, France; Service de Gynécologie-Obstétrique (V.T., F.G.), Université Paris V, Faculté de Médecine, APHP, Hôpital Cochin, Paris, France; Service de Gynécologie-Obstétrique (B.C.), Hôpital Saint Antoine, Paris, France; and the Animal Genetics Department (D.V.), Institut National de la Recherche Agronomique Jouy-en-Josas, France.

Correspondence to Daniel Vaiman, Equipe 21, Génomique et Epigénétique des Pathologies Placentaires, Unité INSERM 567/UMR CNRS 8104, Université Paris V IFR Alfred Jost, Faculté de Médecine, Cochin-Port-Royal, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail vaiman{at}cochin.inserm.fr

Preeclampsia is the major pregnancy-induced hypertensive disorder. It modifies the expression profile of placental genes, including several serine protease inhibitors (SERPINs). The objective of this study was to perform a systematic expression analysis of these genes in normal and pathological placentas and to pinpoint epigenetic alterations inside their promoter regions. Expression of 18 placental SERPINs was analyzed by quantitative RT-PCR on placentas from pregnancies complicated by preeclampsia, intrauterine growth restriction, or both and was compared with normal controls. SERPINA3, A5, A8, B2, B5, and B7 presented significant differences in expression in ≥1 pathological situation. In parallel, the methylation status of the CpG islands located in their promoter regions was studied on a sample of control and preeclamptic placentas. Ten SERPIN promoters were either totally methylated or totally unmethylated, whereas SERPINA3, A5, and A8 presented complex methylation profiles. For SERPINA3, the analysis was extended to 81 samples and performed by pyrosequencing. For the SERPINA3 CpG island, the average methylation level was significantly diminished in preeclampsia and growth restriction. The hypomethylated CpGs were situated at putative binding sites for developmental and stress response (hypoxia and inflammation) factors. Our results provide one of the first observations of a specific epigenetic alteration in human placental diseases and provide new potential markers for an early diagnosis.


Key Words: preeclampsia • intrauterine growth restriction • placenta • serine protease inhibitors • epigenetics




This article has been cited by other articles:


Home page
Reproductive SciencesHome page
B.-Y. Kang, S. Tsoi, Shan Zhu, Shenghui Su, and H. H. Kay
Differential Gene Expression Profiling in HELLP Syndrome Placentas
Reproductive Sciences, March 1, 2008; 15(3): 285 - 294.
[Abstract] [PDF]


Home page
EndocrinologyHome page
C. Buffat, F. Boubred, F. Mondon, S. T. Chelbi, J.-M. Feuerstein, M. Lelievre-Pegorier, D. Vaiman, and U. Simeoni
Kidney Gene Expression Analysis in a Rat Model of Intrauterine Growth Restriction Reveals Massive Alterations of Coagulation Genes
Endocrinology, November 1, 2007; 148(11): 5549 - 5557.
[Abstract] [Full Text] [PDF]